glp 1 agonist lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Eli Lilly: GLP-1R/GCGR/GIPR Triagonist Reduces
Description
Accessed 15 Jan 2022
FOR U.S
Keywords: type 2 diabetes mellitus, GLP-1 receptor agonist, SGLT2 inhibitor, A1c, weight loss, adverse effect Introduction It is estimated that one in three people in the US will develop type 2 diabetes mellitus (T2DM) in their lifetime
For the characterization of time-to-onset distribution patterns, we employed robust statistical descriptors, specifically the median value accompanied by the interquartile range (IQR), to account for potential distributional skewness and outlier effects
